Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15643454 | 0.88 | PRMT5 (0.63) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL2403046 | 0.87 | PRMT5 (0.52) | AHCYADORA2BADORA3DOT1LHSP90B1 | |
| SCHEMBL17460352 | 0.87 | PRMT5 (0.54) | AHCYADORA2BADORA3DOT1L | |
| SCHEMBL22326785 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL18520788 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL29352139 | 0.87 | AHCY (0.63) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL16300875 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL22326787 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL21413837 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A | |
| SCHEMBL13173634 | 0.87 | PRMT5 (0.64) | AHCYADORA2BADORA3DOT1LADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| EP-4384635-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | The Broad Institute Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024086659-A2 | COMPOSITION AND METHODS FOR DETECTING ADENINE MODIFICATIONS | THE UNIVERSITY OF CHICAGO (US) | 2024-04-25 | — | — | WO | claimed |
| US-20240011084-A1 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAs CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY | 2024-01-11 | — | — | US | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| CN-115943307-A | MR1 ligands and pharmaceutical compositions for immunomodulation | 巴塞尔大学 | 2023-04-07 | — | — | CN | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2023018756-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | THE BROAD INSTITUTE, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| WO-2022115822-A2 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAS CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114076805-A | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-02-22 | — | — | CN | claimed |
| WO-2021144475-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2021-07-22 | — | — | WO | claimed |
| CN-104804903-B | Semiconductor cleaning agent with metal line | 恩特格里斯公司 | 2018-10-30 | — | — | CN | claimed |
| CN-106399506-A | Diagnostic methods for determining prognosis of non-small cell lung cancer | 雅培分子公司 | 2017-02-15 | — | — | CN | claimed |
| EP-2755986-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039857-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2001085220-A1 | LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | RNA-TEC N.V. (BE) | 2001-11-15 | — | — | WO | claimed |
| JP-57145898-A | — | — | None | — | — | JP | disclosed |
| JP-S57145898-A | NOVEL N6, N6-DIMETHYLADENOSINE DERIVATIVE | ARAKAWA CHIYOUTAROU KK | 1982-09-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | AHCY 2480/4885ADORA2B 133/4885ADORA3 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.